Skip to content

Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair

Intranasal Ketamine for Procedural Sedation in Pediatric Laceration Repair

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00451724
Enrollment
45
Registered
2007-03-23
Start date
2007-05-31
Completion date
2010-02-28
Last updated
2010-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laceration

Keywords

Prospective, Randomized, Double blinded, Sedation, Ketamine, Intranasal

Brief summary

The purpose of this study is to compare how well three different doses of ketamine, given as a spray into the nose, help to sedate children and help them tolerate repairs of cuts on their faces.

Detailed description

Procedural sedation is frequently used to facilitate distressing and painful procedures in the pediatric emergency department. However, administering an intramuscular medication or placing an intravenous line to give intravenous medications can be as distressing as the procedure itself. Oral medications generally take longer to work and are subject to first-pass metabolism. Another alternative is to give the medication by the intranasal route, which only requires a spray into the nose. Ketamine is a good sedative drug with favorable qualities, and is often used intramuscularly or intravenously. It has been used intranasally as a pre-induction by anesthetics, sedation for CT scans, and brief dental procedures, but its use has not yet been demonstrated in the setting of the pediatric emergency department for procedural sedation. We will be comparing three different doses of ketamine, applied intranasally using a mucosal atomization device, and determining if there are any differences in efficacy of sedation, time to onset of sedation, duration of sedation, caregiver and physician satisfaction, and number of adverse events. We will also use this opportunity to determine ketamine bioavailability when given intranasally using the mucosal atomization device.

Interventions

DRUGIntranasal ketamine

Sponsors

Rhode Island Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
1 Years to 7 Years
Healthy volunteers
Yes

Inclusion criteria

* Children between 1 to 7 years old * Simple facial laceration, defined as: linear; requiring two or more sutures; no greater than 5.0 centimeters; does not cross the lid margin of the eye; does not require a plastics/face surgery consult; occured within the last 24 hours. * Physician feels that intravenous sedation is required to perform the laceration repair

Exclusion criteria

* Closed head injury, any alteration in level of consciousness, clinical suspicion of intracranial injury or increased intracranial pressure * Any conditions that qualify patient as American Society of Anesthesiologists' (ASA) III or IV * Known diagnoses of hyperthyroidism or porphyria * Glaucoma or penetrating eye injury * Hypertension * Any contraindication, including drug allergy, to study medications * Severe trauma with other injuries requiring operative intervention * Abnormal neurological exam in a previously normal child

Design outcomes

Primary

MeasureTime frame
Efficacy of sedation (OSBDR)30 minutes
Time to onset of sedation (Ramsay 6-point Sedation Scale)30 minutes

Secondary

MeasureTime frame
Physician satisfactionDuration of procedure
Ketamine bioavailability1 hour
Duration of sedationUp to 1 hour
Administration of supplemental sedative medicationDuring time required for procedure
Prolonged sedation (i.e. > 1 hour)Until time of discharge from emergency department
Abnormalities in cardiopulmonary functionUntil time of discharge
Primary caregiver satisfaction24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026